Efficacy and Safety for Use Desloratadine in Children with Allergic Conditions (Literature Review, Own Research)
DOI:
https://doi.org/10.30841/2307-5112.5-6.2020.225468Keywords:
children, allergic disease, treatments, antihistamine drugs, desloratadine (Edem)Abstract
According to scientists, more than 20 thousand allergens are known and their number is constantly increasing. Therefore, children’s allergy remains one of the urgent problems of modern medicine, since allergic diseases in adults in most cases begin from childhood.
The article summarizes our own data and presents a scientific review of the medical literature, which is devoted to the analysis of the problem of treatment of allergic diseases with desloratadine in children. Nowdays there is a significant prevalence of allergic conditions in children. We analyzed the effect of desloratadine on the course of allergic diseases in children. The analyzed literature review showed a high safety profile of the drug desloratadine. Also we presented the personal data of desloratadine therapy for seasonal allergic rhinitis in children.
The literature data presented in the article and our own experience allow us to conclude that allergic conditions remain an urgent problem in clinical medicine, and the use of antihistamines, in particular desloratadine, increases the effectiveness of allergy therapy and accelerates the recovery and disappearance of symptoms.
References
Швецова Е.С., Короткова Т.С. Распространенность аллергических заболеваний среди всех возрастных групп населения Липецкой области. Современные проблемы науки и образования. 2017. № 4. С. 45–51.
Беш Л.В. Алергічний риніт у дітей. Здоровье ребенка. 2012. № 5 (40). С. 35–37.
Марушко Ю.В., Московенко О.Д. Комплексні препарати в терапії гострого риніту у дітей. Современная педиатрия. 2016. № 2 (74). С. 84–88.
Эрназарова Х., Хумроевна А. Распространенность аллергических заболеваний в мире. International scientific review. 2017. № 3. С. 15–19.
Гущин И.С., Курбачева О.М. Аллергия и аллерген-специфическая иммунотерапия. Фармарус Принт Медиа. 2010. С. 228.
25-й ежегодный Конгресс ЕААСІ (Вена, Австрия, 10–14 июня 2006 г.) «Аллергический ринит» // Клінічна імунологія. Алергологія. Інфектологія. 2006. № 2 (03). С. 62–64.
Мурзина Э.А. Современные антигистаминные препараты в лечении заболеваний аллергической природы. Внутренняя медицина. 2008. № 3 (9). С. 20–25.
Савченко В. Эффективность и безопасность дезлоратадина у детей. Обзор доказательной базы. Здоров’я України. 2011. № 2 (17). C. 47.
Гущин И.С. Перспективы совершенствования противоаллергического действия Н1-антигистаминных препаратов. Леч. врач. 2009. № 5. С. 34–40.
Марушко Ю.В., Московенко О.Д. Характеристика сенсибілізації і досвід використання дезлоратадину в лікуванні сезонного алергічного риніту в дітей. Здоровье ребенка. 2019. № 7. С. 54–57.
Niu S, Li Y, Dong W, Xia L, Shen T, Wang J, at all. A randomized study on the bioequivalence of desloratadine in Chinese healthy subjects and the association of different metabolic phenotypes with UGT2B10 and CYP2C8 genotypes. Curr Drug Metab. 2020. P. 1031–1039.
Molimard M., Diquet B. Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 2004. № 18. P. 399–411.
Bartra J., Valero A.L., Cuvillo A., Dávila I. Interactions of the H1 antihistamines. J. Investig. Allergol. Clin. Immunol. 2006. № 16. Р. 29–36.
Berginc К., Sibinovska N., Žakelj S., Trontelj J., Legen I. Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way. Acta Pharmaceutica. 2020. V. 70. Issue 2.
Kreutner W, Hey J.A., Anthes J., Barnett A., Young S., Tozzi S. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung. 2000. №50. Р. 345–352.
Andersson N.W., Poulsen H.E., Andersen J.T.J. Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study. Allergy Clin Immunol Pract. 2020. №8(5). Р. 1598–1605.
Ma J., Qi J., Li S., Zhang C., Wang H., Shao L., Yuan X., Sha Q. Desloratadine, a Novel Antigrowth Reagent for Bladder Cancer. Technol Cancer Res Treat. 2020. № 2. Р. 123–132.
Geha R.S., Meltzer E.O. Desloratadine: A new, nonsedating, oral antihistamine. Allergy Clin Immunol. 2001. № 107(4). Р. 751–62.
Jie Q., Kodithuwakku N.D., Yuan X., He G., Chen M., Xu S., Wu Y., Eur J. Antiallergic and anti-inflammatory properties of a potent histamine H1 receptor antagonist, desloratadine citrate disodium injection, and its anti-inflammatory mechanism on EA.hy926 endothelial cells. Pharmacol. 2015 № 5. Р. 1–10.
Uehara S., Yoneda N., Higuchi Y., Yamazaki H., Suemizu H. Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. Xenobiotica. 2020. № 50 (6). Р. 733–740.
Meltzer E.O., Prenner B.M., Nayak A. Efficacy and tolerability of once-daily 5 mg desloratadine, an h1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest. 2001. № 21. Р. 25–32.
Salmun L.M., Lorber R. 24-Hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam. Pract. 2002. № 3. Р. 14.
Nayak A.S., Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy. 2001. № 56. Р. 1077–1080.
Berger W.E., Schenkel E.J., Mansfield L.E. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy Asthma Immunol. 2002. №89. Р. 485–491.
Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy. 2000. №56. Р. 14–20.
Baena-Cagnini C.E., Berger W.E., Dubuske L.M. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int. Arch. Allergy Immunol. 2003. № 130. Р. 307–313.
Ring J., Hein R., Gauger A., Bronsky E., Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebocontrolled study. Int. J. Dermatol. 2001. № 40. Р. 72–76.
Monroe E., Finn A., Patel P., Guerrero R., Ratner P., Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 2003. № 48. Р. 535–541.
DuBuske L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopatic urticaria and allergic inflammatory disorders. Expert Opin. Pharmacother. 2005. № 6(14). Р. 2511–23.
Вousquet J., Bachert C., Canonica G.W. ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis – a GA2LEN study. Int. Arch. Allergy Immunol. 2010. № 153(4). Р. 395–402.
González-Núñez V., Valero A., Mullol J. Safety evaluation of desloratadine in allergic rhinitis. Expert Opin Drug Saf. 2013 № 12 (3). Р. 445–53.
Clellan K.Mc., Jarvis В. Desloratadine. Drugs. 2001. № 61 (6). Р. 789–96.
Iriarte Sotés Р., Armisén М., Usero-Bárcena Т. Up-Dosing Antihistamines in Chronic Spontaneous Urticaria: Efficacy and Safety. A Systematic Review of the Literature. J Investig Allergol Clin Immunol. 2020.
Nakamura Т., Hiraoka К., Ryuichi H. Brain histamine H 1 receptor occupancy after oral administration of desloratadine and loratadine. Pharmacol Res Perspect. 2019. № 12. 7(4).
Сміян О.І., Бинда Т.П. Застосування Едему у комплексній терапії алергічних захворювань. Здоров’я України. 2014. № 4(39). С. 35–38.
Буряк В.Н., Пошехонова Ю.В., Шабан Н.И., Дудко М.В., Скачкова Л.П., Бессараб П.А. Опыт оптимизации патогенетической терапии атопического дерматита в детском возрасте. Здоровье ребенка. 2011. № 4(31). С. 32–37.
Bagheri H., Simiand E. Adverse Drug Reactions to Anthelmintics. Annals of Pharmacotherapy. 2004. № 38 (3). P. 383–388.
Крамарьов С.О., Закордонець Л.В. Гельмінтози в дітей: підходи до лікування. Здоров’я дитини. 2018. Т. 13, № 3.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Yurii Marushko, Olha Khomych
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal does not require authors of original (primary) research papers to assign the copyright of their published contributions. Authors grant the journal an non-exclusive licence CC BY 4.0 (Creative Commons Attribution 4.0 International License) to using and the first publication of the original in this journal. Copyright of the manuscripts is retained by the authors, after publication authors retain rights to reuse their papers in their future printed work without first requiring permission from the publisher of the journal and share their own published articles.
The journal supports the self-archiving process. Prior to publication in the journal, authors may post a copy of their manuscript in preparation or submitted to the journal in recognized non-commercial preprint servers, public websites. Authors also are encouraged to archive their final author version of the manuscript in their institution's repositories and, if they wish, on their personal websites. Authors should cite the publication reference and DOI number on the first page of any deposited version, and provide a link from it to the URL of the published article on the journal's website.
To facilitate self-archiving of original research papers and help authors fulfil funder and institutional mandates, the journal deposits manuscripts in National Library of Ukraine by V.I. Vernadsky, Scientific periodicals of Ukraine database and different international scintificd database on behalf of authors who opt-in to this free service during submission. The journal provides depositing of articles on official website of the publisher. The full text access to published papers is free.
